This suggests downregulation of BCAA metabolism in HF, particularly in ICM-DM, and may explain the upregulation of myocardial BCAAs in HF, as previously indicated in end-stage NICM (Flam et al, 2022) whereby increased tissue BCAA may impair insulin sensitivity (Uddin et al, 2019). The gene discussed is INS; the disease is diabetes mellitus.